

## Medidata Expands Partnership with BeiGene to use Medidata's Patient Cloud ePRO Solution

*Expanded Partnership Includes Medidata Patient Cloud ePRO to Seamlessly Collect Patient-Centric Data and Automate Manual Processes for Oncology Research*

NEW YORK--(BUSINESS WIRE)-- [Medidata](#) (NASDAQ:MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, today announced that [BeiGene](#), Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, will expand its use of the [Medidata Clinical Cloud](#)® to further digitize patient reporting for its oncology research studies.

BeiGene will leverage Medidata's integrated platform to feed eSource Patient Reported Outcome data from [Medidata's Patient Cloud ePRO](#) directly into [Medidata Rave](#)®. This infusion of patient recorded outcome data will enable improved operational efficiency, reduced transcription errors and reconciliation issues, and decreased data quality risk plans.

"Our expanded partnership with Medidata will establish a technology platform for our clinical research, which we expect will enable us to more efficiently execute clinical trials of our portfolio compounds," said Ross Pettit, Senior Vice President of Global Development Operations at BeiGene. "Over the past two years, Medidata has proven to be a key technology partner for BeiGene, with its industry-leading solutions and hands-on approach to our integration needs. By automating paper-based procedures and centralizing patient data on the Medidata platform, we're able to collaborate globally on our oncology research."

As part of its expanded partnership with Medidata, BeiGene also plans to standardize the collection and management of safety cases through [Medidata Safety Gateway](#)®, a secure, configurable electronic transmission interface between EDC and safety systems. The partnership between BeiGene and Medidata also includes [Medidata Coder](#)®, a cloud application that is designed to streamline and centralize medical coding to perform oncology research studies.

"Medidata is proud to be accelerating technology advancement at every level and interaction within the life sciences industry," said Kara Dennis, Managing Director of Mobile Health at Medidata. "We've created an environment that is agile, globally collaborative, and in line with the digital and mobile needs of biotechnology and pharmaceutical companies, all from one unified cloud platform. BeiGene's forward-thinking technology approach will enable faster study builds and centralized control over patient data, facilitating the evaluation of its portfolio compounds."

### About Medidata

[Medidata](#) is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 850 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.

The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers—from study design and planning through execution, management and reporting.

### About BeiGene

BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients.

**Medidata Solutions**

Investors:

Anthony D'Amico, +1 732-767-4331

[adamico@mdsol.com](mailto:adamico@mdsol.com)

or

Media:

Erik Snider, +1 646-362-2997

[esnider@mdsol.com](mailto:esnider@mdsol.com)

Source: Medidata

News Provided by Acquire Media